Early efficacy shown for Sanofi/Regeneron asthma/dermatitis antibody
This article was originally published in Scrip
Executive Summary
Early clinical data for Sanofi/Regeneron’s dupilumab appear to support the targeting of IL-4R as a promising therapeutic avenue in atopic dermatitis, the companies say.